The company granted stock options to purchase an aggregate of 208,350 shares of Nurix common stock and restricted stock unit ...

The event will be webcast live and may be accessed via a link in the Investors section of the Nurix website. The archived webcast will be available for 30 days after the event. About Nurix ...

Mechanically, we demonstrated that E3 ligase TNF receptor–associated factor 6 (TRAF6 ... HRP-conjugated goat anti-mouse or anti-rabbit secondary antibodies for Western blot were purchased from Santa ...

Nurix's wholly owned, clinical stage pipeline includes degraders of Bruton's tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), ...

During HBV infection, the outcome of infection is ultimately determined by HBV-specific antibody producing B cells and functional ... HBeAg and its precursor preCore/p22 interact with NUMB to promote ...

Ideally, the immune system will produce long-lasting antibodies recognizing that specific virus, thereby providing protection. But Scripps Research scientists have now discovered that for some HIV ...

E3-ubiquitin ligase inducible degrader of the LDL receptor has a similar function to PCSK9 and is a potential therapeutic target. A desirable treatment target for HoFH patients is LDL-C ≤1.8 mmol/l.

No writing assistance was utilized in the production of this manuscript. Monoclonal antibodies are novel therapeutic agents used with great success in the treatment of rheumatoid arthritis (RA).